Dementia - Articles - Page 3 | CARLAT PUBLISHING

How to Interview the Older Patient

January 1, 2022

Rehan Aziz, MD. Inpatient geriatric psychiatry, Hackensack-Meridian Health, Perth Amboy, NJ. Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The expanding population of older adults has created a need for all clinicians to participate in their care. Interviewing techniques require adaptation in older adults, such as accounting for hearing or vision impairment and speaking slowly and clearly. This article will cover additional factors to consider when evaluating older patients.

In the News: Aducanumab (Aduhelm)

November 5, 2021

Rehan Aziz, MD.

Rehan Aziz, MD. Associate professor of psychiatry and neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When the FDA approved aducanumab (Aduhelm) in Alzheimer dementia, the decision came with a heavy dose of controversy. Rehaz Aziz, MD, considers where this novel therapy fits in practice.

In Brief: Meds in the Fast Lane

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.

In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.

Q&A

Treating Agitation in Patients with Dementia

September 13, 2021

Eran Metzger, MD

Eran Metzger, MD

Medical Director of Psychiatry, Hebrew SeniorLife, Boston, MA. Assistant Professor of Psychiatry, Harvard Medical School, Boston, MA.

Dr. Metzger has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The behavioral and psychological symptoms of dementia can be challenging to manage. Dr. Metzger discusses his approach in the diagnosis and treatment of agitated patients with dementia.

Anticholinergic Drugs and Risk of Cognitive Impairment and Dementia

September 13, 2021

Shelly L. Gray, PharmD

Shelly L. Gray, PharmD

Professor and Plein Endowed Director, Plein Center for Geriatric Pharmacy Research, School of Pharmacy, University of Washington, Seattle, WA.

Dr. Gray has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Might anticholinergic medications increase the risk of long-term cognitive impairment? Dr. Gray reviews the data.

Note From the Editor-in-Chief

September 13, 2021

Victoria Hendrick, MD.

Victoria Hendrick, MD. Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center. Dr. Hendrick has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Sometimes we have little choice but to administer sedating medications to a combative patient who is putting others at risk of injury. Which medications work most quickly, safely, and effectively?

Rest Easy: Benzos, Z-Drugs, and Dementia

December 31, 2020

James Jenkins, MD.

James Jenkins, MD. Dr. Jenkins has disclosed that he has stock in Alkermes, Sage Therapeutics, Teva Pharmaceutical Industries, Trevena, and Viatris. Dr. Aiken has reviewed this article and has found no evidence of bias pertaining to this educational activity.

It may not be perfect, but this study has the best data yet on the controversial link between benzodiazepines and dementia.

Agitation in Dementia (Part 2)

February 20, 2020

Families bring difficult questions when their loved one has dementia, and in this interview with Cathy Howard, RN, we’ll show you how to answer some of them. We also delve into the nonpharmacologic approaches to agitation in dementia to learn what they look like in real life.Published On: 2/20/20Duration: 8 minutes, 9...

Agitation in Dementia (Part 1)

February 17, 2020

Nuedexta. A 60 year old cough medicine gets approve for uncontrollable crying, but the drug company has its eyes on a bigger target: Agitation in dementia. Follow the trail of pseudoscience, bribery, and indictments, and learn a few clinical pearls about this dextromethorphan-quinidine combination along the way.Published On: 2/17/20Duration: 15 minutes, 51...

Nuedexta in Agitated Dementia

February 10, 2020

Nuedexta is indicated for pseudobulbar affect, but when the manufacturer attempted to expand its use into agitation in dementia they ran into some heavy legal penalties. Here we take a closer look at the published and unpublished trials to see what ─ if anything ─ is salvageable. We’ll also show you how to prescribe this high-cost drug as a generic equivalent.